Cargando…

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission

Background Natural Killer (NK) cells are innate lymphoid cells that can be cytotoxic toward a large panel of solid tumors and hematological malignancies including chronic myeloid leukemia (CML). Such a cytotoxicity depends on various receptors. Killer immunoglobulin‐like receptors (KIR) belong to th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dumas, Pierre‐Yves, Bérard, Emilie, Bréal, Claire, Dulucq, Stéphanie, Réa, Delphine, Nicolini, Franck, Forcade, Edouard, Dufossée, Melody, Pasquet, Jean‐Max, Turcq, Béatrice, Bidet, Audrey, Milpied, Noel, Déchanet‐Merville, Julie, Lafarge, Xavier, Etienne, Gabriel, Mahon, François‐Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718597/ https://www.ncbi.nlm.nih.gov/pubmed/31287239 http://dx.doi.org/10.1002/cam4.2371

Ejemplares similares

α-Defensin 1-3 And α-Defensin 4 as Predictive Markers of Imatinib Resistance and Relapse in CML Patients
por: Etienne, Gabriel, et al.
Publicado: (2011)

The pharmacogenetics of imatinib
por: Dulucq, Stéphanie, et al.
Publicado: (2010)

Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
por: Dulucq, Stéphanie, et al.
Publicado: (2016)

What is treatment free remission in chronic myeloid leukemia?
por: Rea, Delphine, et al.
Publicado: (2017)

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
por: Dulucq, Stéphanie, et al.
Publicado: (2022)

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission
por: Dulucq, Stephanie, et al.
Publicado: (2022)

Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL
por: Dumas, Pierre-Yves, et al.
Publicado: (2019)

A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib
por: Augis, Vanessa, et al.
Publicado: (2013)

Editorial: “Recent Advances in Gamma/Delta T Cell Biology: New Ligands, New Functions, and New Translational Perspectives”
por: Kabelitz, Dieter, et al.
Publicado: (2015)

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia
por: Dumas, Pierre-Yves, et al.
Publicado: (2017)

γδ T Cell-Mediated Immunity to Cytomegalovirus Infection
por: Khairallah, Camille, et al.
Publicado: (2017)

Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation
por: Couzi, Lionel, et al.
Publicado: (2015)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients
por: Etienne, Gabriel, et al.
Publicado: (2020)

Key Features of Gamma-Delta T-Cell Subsets in Human Diseases and Their Immunotherapeutic Implications
por: Lawand, Myriam, et al.
Publicado: (2017)

Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis
por: Calmettes, Claire, et al.
Publicado: (2018)

Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report
por: Park, Hyerin, et al.
Publicado: (2021)

Relevance of treatment‐free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2021)

Treatment-free remission: A new goal for all chronic phase (CP)-CML patients
por: Rea, Delphine
Publicado: (2018)

Novel analytical methods to interpret large sequencing data from small sample sizes
por: Lichou, Florence, et al.
Publicado: (2019)

Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study
por: Goni, Deepak, et al.
Publicado: (2023)

Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
por: Cortes, Jorge, et al.
Publicado: (2018)

Mycophenolic Acid Overcomes Imatinib and Nilotinib Resistance of Chronic Myeloid Leukemia Cells by Apoptosis or a Senescent-Like Cell Cycle Arrest
por: Drullion, Claire, et al.
Publicado: (2012)

Complete remission of a periorbital dermatofibrosarcoma protuberans with adjuvant imatinib mesylate in a child
por: Yen, Hsi, et al.
Publicado: (2015)

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
por: Rea, Delphine, et al.
Publicado: (2017)

Uncovering the Anticancer Potential of Murine Cytomegalovirus against Human Colon Cancer Cells
por: Massara, Layal, et al.
Publicado: (2020)

Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes in db/db Mice
por: Han, Myoung Sook, et al.
Publicado: (2009)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
por: Fernandez, Solène, et al.
Publicado: (2019)

Enhancing Production and Cytotoxic Activity of Polymeric Soluble FasL-Based Chimeric Proteins by Concomitant Expression of Soluble FasL
por: Morello, Aurore, et al.
Publicado: (2013)

Human Vγ9Vδ2 T Lymphocytes in the Immune Response to P. falciparum Infection
por: Howard, Jennifer, et al.
Publicado: (2018)

Shared reactivity of Vδ2(neg) γδ T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells
por: Halary, Franck, et al.
Publicado: (2005)

Does Inflammation Contribute to Cancer Incidence and Mortality during Aging? A Conceptual Review
por: Guerville, Florent, et al.
Publicado: (2022)

Cost comparison of post-remission strategies in younger and older AML patients in France
por: Mounie, Michael, et al.
Publicado: (2023)

Impact of Mutational Status and Prognostic Factors on Survival in Chronic Myelomonocytic Leukemia With Systemic Inflammation and Autoimmune Disorders
por: Dussiau, Charles, et al.
Publicado: (2023)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021)

Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence
por: Drullion, C, et al.
Publicado: (2012)

The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation
por: Mansier, Olivier, et al.
Publicado: (2019)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Relapse After Cessation of Immunosuppressants in Seropositive Neuromyelitis Optica Spectrum Disorder With Long-Term Remission
por: Seok, Jin Myoung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dvvspcoh6mvhubrhba5d9u3i0u